Why Early mAb Sequence Optimization can Improve Developability and Reduce Costs
Read the article on why early mAb optimization might be right for your project.
Learn more
Flexible, Continuous Manufacturing Technologies
Read the article our continuous manufacturing technologies used in our cGMP manufacturing facility J.POD.
Biologics Manufacturing Without the Big Bioreactors
Read the article on our cGMP manufacturing facility J.POD in the June edition of BioProcess Int.
Automated multi-attribute method sample preparation using high-throughput buffer exchange tips
In recent years, the multi-attribute method (MAM) has become an important mass spectrometry-based tool for identifying and quantifying the site-specific product attributes and purity information…
Development of recombinase-based targeted integration systems for production of exogenous proteins using transposon-mediated landing pads
Journal: Current Research in Biotechnology (CRBIOT)
Evotec publishes DDup 11 – AI-driven antibody discovery at Evotec
The 11th edition is dedicated to our exciting new capabilities in the biologics lane of Evotec’s “Multi-modality Autobahn.” For the biologics industry, Evotec provides a…
Introduction to Antibodies
What are antibodies? Antibodies, or immunoglobulin molecules, are glycoproteins produced by the plasma B cells of the adaptive immune system with the aim to recognise…
AI-driven antibody discovery at Evotec
Antibody discovery may be driven by the interrogation of two primary sources: (1) in vivo (animal-derived B cells) or (2) in vitro (library-derived antibody display…
Function-focused antibody (FFmab) screening
What is FFmab screening? FFmab screening is a platform for identifying novel functional antibodies that change disease-modifying phenotypes of immune cells. The platform identifies innovative…
Interview with Dr Jim Thomas and Karen Lackey
What role do Biologics play in the context of novel therapeutics? Jim: Biologics are a significant and growing portion of the arsenal of therapeutics used…
Interview with Barbara Bachler-Konetzki about Evotec’s integrated antibody discovery capabilities
What were the limitations of previous hybridoma-based approaches? Although the development of the hybridoma technology was a landmark event, the methodology still faced the limitation…
Interview with RANDAL R. KETCHEM about the optimization of antibodies
How does optimization of antibodies improve development? Just – Evotec Biologics has developed a molecular optimisation platform for monoclonal antibodies to increase productivity, eliminate potential…